New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening.
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
14 02 2022
14 02 2022
Historique:
pubmed:
6
2
2022
medline:
15
3
2022
entrez:
5
2
2022
Statut:
ppublish
Résumé
Cancers other than breast, colorectal, cervical, and lung do not have guideline-recommended screening. New multi-cancer early detection (MCED) tests-using a single blood sample-have been developed based on circulating cell-free DNA (cfDNA) or other analytes. In this commentary, we review the current evidence on these tests, provide several major considerations for new MCED tests, and outline how their evaluation will need to differ from that established for traditional single-cancer screening tests.
Identifiants
pubmed: 35120599
pii: S1535-6108(22)00014-9
doi: 10.1016/j.ccell.2022.01.012
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Letter
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-113Subventions
Organisme : Cancer Research UK
ID : C444/A15953
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests C.A.C. is an employee of GRAIL, LLC, and holds stock in the company. A.-R.H. is a former employee of GRAIL and holds stock in the company and is currently employed by Adela, Inc. A.H. is an investigator for an academic study (SUMMIT) sponsored by University College London that is funded by GRAIL, has received one honorarium for an advisory board meeting for GRAIL, received a consulting fee from Evidera Inc. (for a GRAIL-initiated project), and has previously owned shares in Illumina, Inc. He did not receive any compensation for his work on this manuscript. A.H. is supported by a Cancer Research UK grant to University College London (C444/A15953).